Decisions may need to be made about issuing EUAs for one or more vaccines, with data that are promising but incomplete. Questions about risk and benefit, either for entire populations or for high-risk subgroups, must be discussed openly, among independent experts, using all available data, with clear acknowledgment of what is known and what is as yet unknown. Decisions about licensure of COVID-19 vaccines should similarly be made with VRBPAC engagement, review, and advice.
COVID-19 Prevention Network (CoVPN) Website is Live The COVID-19 Prevention Network (CoVPN) has launched an interactive website to provide information about Phase 3 vaccine and monoclonal antibody efficacy studies for the prevention of COVID-19. The site, launched on July 8, 2020 educates potential study participants about COVID-19, what to expect when volunteering in clinical trials […]
Dr. Ruth Karron is scheduled to testify at the House Subcommittee virtual briefing, “Guardrails to Ensure a Safe and Effective COVID-19 Vaccine”
In the recent article: “Influenzers in Action: COVID-19 Response-Celebrating Influenza through Leaders and Advocates”, CIR’s Director Dr. Ruth Karron’s work in vaccine research and policy was recognized among leaders in the field of vaccine research. The article celebrates the contributions being made by visionary thought leaders in vaccine science, public health policy, and pandemic preparedness […]
Dr. Anna Durbin Discusses COVID-19 Vaccine Development with Bill Nye Dr. Anna Durbin recently participated in a podcast with Bill Nye best known from the hit TV show Bill Nye the Science Guy. Dr. Durbin and Bill Nye discuss COVID19 vaccine development, Project WARP Speed and what it will take to have a successful roll […]
Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and […]
Dr. Ruth Karron Discusses COVID-19 Vaccine Development The traditional vaccine development process can take up to 20 years to produce a safe and effective vaccine for use in the general public. Scientists have been looking for ways to shorten the period of time it takes to produce a viable vaccine once a virus with pandemic […]
“There are aspects of the trials that just can’t be rushed. It takes time to develop an immune response to the vaccine, and it also takes time to evaluate the safety of these vaccines.”